Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $329.98 | 5 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $199.98 | 2 | $0 (2021) |
| Amgen Inc. | $99.99 | 1 | $0 (2018) |
| Merck Sharp & Dohme LLC | $18.09 | 1 | $0 (2024) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18.09 | 1 | Merck Sharp & Dohme LLC ($18.09) |
| 2021 | $211.90 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($199.98) |
| 2018 | $99.99 | 1 | Amgen Inc. ($99.99) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 04/21/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Education | In-kind items and services | $99.99 | General |
| 04/21/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Education | In-kind items and services | $99.99 | General |
| 05/22/2018 | Amgen Inc. | — | Education | In-kind items and services | $99.99 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 494 | 1,061 | $335,520 | $102,092 |
| 2022 | 25 | 990 | 66,523 | $1.8M | $640,437 |
| 2021 | 24 | 862 | 55,590 | $657,362 | $207,938 |
| 2020 | 36 | 1,209 | 52,507 | $864,755 | $251,467 |
All Medicare Procedures & Services
92 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 379 | 917 | $279,685 | $85,676 | 30.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 37 | 58 | $23,790 | $8,258 | 34.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $7,800 | $2,626 | 33.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 18 | $8,550 | $2,465 | 28.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 22 | $3,906 | $1,374 | 35.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 19 | $4,085 | $1,011 | 24.7% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 11 | 12 | $7,704 | $681.85 | 8.9% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2022 | 11 | 10,200 | $978,205 | $422,836 | 43.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 347 | 798 | $241,920 | $77,165 | 31.9% |
| Q5108 | Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg | Office | 2022 | 15 | 408 | $141,808 | $54,831 | 38.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 50 | 204 | $146,340 | $23,324 | 15.9% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2022 | 15 | 14,280 | $24,864 | $9,149 | 36.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 112 | 138 | $29,319 | $9,009 | 30.7% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2022 | 18 | 37,740 | $48,931 | $8,084 | 16.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 42 | 56 | $22,464 | $8,045 | 35.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 37 | 89 | $29,642 | $5,019 | 16.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $8,700 | $2,845 | 32.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 41 | 207 | $21,381 | $2,736 | 12.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 15 | 45 | $15,318 | $2,499 | 16.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 56 | 210 | $24,764 | $2,413 | 9.7% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2022 | 18 | 50 | $16,232 | $2,400 | 14.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $6,176 | $2,110 | 34.2% |
| M0220 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | Office | 2022 | 11 | 11 | $7,810 | $1,485 | 19.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 15 | 59 | $8,409 | $1,476 | 17.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 17 | 51 | $7,546 | $1,231 | 16.3% |
About Gautami Rao, M.D.,
Gautami Rao, M.D., is a Hematology & Oncology healthcare provider based in Nashua, New Hampshire. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497862569.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Gautami Rao, M.D., has received a total of $329.98 in payments from pharmaceutical and medical device companies, with $18.09 received in 2024. These payments were reported across 5 transactions from 4 companies. The most common payment nature is "Education" ($329.98).
As a Medicare-enrolled provider, Rao has provided services to 3,555 Medicare beneficiaries, totaling 175,681 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 92 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Nashua, NH
- Active Since 08/24/2006
- Last Updated 10/15/2009
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1497862569
Products in Payments
- KEYTRUDA (Biological) $18.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Nashua
Nancy Chun, Md, MD
Hematology & Oncology — Payments: $7,026
Yugandhara Kate, Md, MD
Hematology & Oncology — Payments: $573.74
Can Wang
Hematology & Oncology — Payments: $107.82
Dr. Mary Voltz, M.d, M.D
Hematology & Oncology — Payments: $102.76